Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akari Therapeutics ADR (AKTX)

Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,230
  • Shares Outstanding, K 26,593
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,790 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0301 +35.91%
on 04/21/25
1.5800 -11.39%
on 04/22/25
+0.3300 (+30.84%)
since 04/11/25
3-Month
0.8500 +64.71%
on 03/03/25
1.7300 -19.08%
on 03/20/25
+0.3132 (+28.82%)
since 02/13/25
52-Week
0.8500 +64.71%
on 03/03/25
4.4000 -68.18%
on 07/26/24
-0.0900 (-6.04%)
since 05/13/24

Most Recent Stories

More News
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

AKTX : 1.4000 (-0.71%)
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

AKTX : 1.4000 (-0.71%)
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

AKTX : 1.4000 (-0.71%)
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment

A London-based %Healthcare company found success Thursday after the company announced that it had appointed a new CEO. The new executive is Abizer Gaslightwala, who was most recently senior vice president...

AKTX : 1.4000 (-0.71%)
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

AKTX : 1.4000 (-0.71%)
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

AKTX : 1.4000 (-0.71%)
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AKTX : 1.4000 (-0.71%)
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies here

AKTX : 1.4000 (-0.71%)
AREC : 0.8790 (+5.28%)
OTLK : 2.0300 (+27.67%)
AMIX : 1.8500 (+5.71%)
CNSP : 1.3600 (+12.40%)
PALI : 0.7301 (-5.06%)
NVNO : 3.83 (+6.09%)
HURA : 4.10 (+7.33%)
GRI : 1.4900 (-3.87%)
Akari Therapeutics Joins Webull Corporate Connect Service Platform

AKTX : 1.4000 (-0.71%)
Akari Therapeutics Announces Appointment of Samir R. Patel, M.D. as CEO and Abizer Gaslightwala to Board of Directors

Akari Therapeutics announces Samir R. Patel as CEO and Abizer Gaslightwala's appointment to the Board of Directors.Quiver AI SummaryAkari Therapeutics, Plc announced the appointment of Samir R. Patel,...

AKTX : 1.4000 (-0.71%)

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

3rd Resistance Point 1.4835
2nd Resistance Point 1.4468
1st Resistance Point 1.4234
Last Price 1.4000
1st Support Level 1.3633
2nd Support Level 1.3266
3rd Support Level 1.3032

See More

52-Week High 4.4000
Fibonacci 61.8% 3.0439
Fibonacci 50% 2.6250
Fibonacci 38.2% 2.2061
Last Price 1.4000
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar